<DOC>
	<DOCNO>NCT01191268</DOCNO>
	<brief_summary>The purpose study assess efficacy safety LY2189265 comparison Insulin Glargine , combination Insulin Lispro ( plus minus Metformin ) , participant Type 2 Diabetes treat 1 2 injection insulin .</brief_summary>
	<brief_title>A Study Participants With Type 2 Diabetes Mellitus ( AWARD-4 )</brief_title>
	<detailed_description>The term rescue therapy trial define therapy participant meet criterion persistent severe hyperglycemia therapy participant require new intervention reason . The latter include participant discontinue study drug due adverse event , participant decision , reason . For efficacy analysis , participant receive rescue medication include analysis population , measurement obtain prior take rescue therapy include efficacy analysis . For safety analysis , exception hypoglycemia , measurement include obtain take rescue therapy include analysis .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes Currently use insulin least 3 month conventional insulin regimen without oral medication Glycosylated hemoglobin ( HbA1c ) great equal 7 % less equal 11 % Willing inject subcutaneous medication Willing monitor blood glucose level adjust insulin dose Willing maintain study diary Body mass index ( BMI ) 23 45 kilogram per square meter ( kg/m^2 ) Stable weight 3 month prior screen Females child bear potential must test negative pregnancy screen willing use reliable method birth control study 1 month follow last dose study drug Type 1 Diabetes Previous therapy glucagonlike peptide 1 ( GLP1 ) agonists within 3 month prior screen 1 episode ketoacidosis within 6 month prior screen Have treat prescription counter medication promote weight loss within 3 month prior screen Estimated glomerular filtration rate ( eGFR ) less equal 30 milliliter per minute per 1.73 square meter ( mL/min/1.73 m^2 ) screen Taking steroid great 14 day except topical , eye , nasal , inhaled History heart failure , New York Heart Classification III IV within 2 month prior screen Gastrointestinal ( GI ) problem diabetic gastroparesis bariatric surgery ( stomach staple ) chronically take medication directly affect GI motility Acute chronic hepatitis pancreatitis Self family history 2A type 2B multiple endocrine neoplasia medullary CCell hyperplasia Serum calcitonin great equal 20 picograms per milliliter ( pcg/mL ) screen Organ transplant except cornea Significant active autoimmune disease Lupus Rheumatoid Arthritis History active malignancy except skin situ cervical prostate cancer within last 5 year Known drug alcohol abuse Have enrol another clinical trial within last 30 day Have previously sign informed consent participate LY2189265 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>